Last reviewed · How we verify
FEX60/PE10
FEX60/PE10 is a fixed-dose combination of fexofenadine (a selective H1-receptor antagonist) and pseudoephedrine (a sympathomimetic decongestant) that reduces allergic symptoms and nasal congestion.
FEX60/PE10 is a fixed-dose combination of fexofenadine (a selective H1-receptor antagonist) and pseudoephedrine (a sympathomimetic decongestant) that reduces allergic symptoms and nasal congestion. Used for Allergic rhinitis with nasal congestion.
At a glance
| Generic name | FEX60/PE10 |
|---|---|
| Sponsor | Sanofi |
| Drug class | Antihistamine/decongestant combination |
| Target | H1 receptor (fexofenadine); alpha-1 adrenergic receptor (pseudoephedrine) |
| Modality | Small molecule |
| Therapeutic area | Allergy/Immunology |
| Phase | Phase 3 |
Mechanism of action
Fexofenadine blocks H1 histamine receptors to reduce itching, sneezing, and urticaria associated with allergies, while pseudoephedrine acts as an alpha-adrenergic agonist to constrict nasal blood vessels and relieve nasal congestion. This combination addresses both the allergic response and the mechanical obstruction of allergic rhinitis.
Approved indications
- Allergic rhinitis with nasal congestion
Common side effects
- Headache
- Nervousness or insomnia
- Dry mouth
- Tachycardia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FEX60/PE10 CI brief — competitive landscape report
- FEX60/PE10 updates RSS · CI watch RSS
- Sanofi portfolio CI